nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

Home nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors

/ Publications

Share the Post

About the Author

Related Posts

Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database
Baiteng Zhao, PhD
Real-world analysis of patients with advanced gastrointestinal cancers harboring inactivating alterations in TSC1 and TSC2 using the Foundation Medicine genomic database
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program
ABI-009, nab-Sirolimus, an mTOR Inhibitor with High Lung Accumulation in Preclinical Models: Initial Results from an Ongoing Phase I/II Safety and Preliminary Efficacy Study in Severe PAH
Aadi Bioscience to Announce First Quarter 2022 Financial Results on May 12, 2022
cache
cache

Comments

Comments are closed.